LIFEVANTAGE CORP APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
LIFEVANTAGE CORP (LFVN) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $800.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2024-05-02
- LIFEVANTAGE CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-03-31 was $800.00K, a 0.00% change year-over-year.
- LIFEVANTAGE CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-12-31 was $800.00K, a 0.00% change year-over-year.
- LIFEVANTAGE CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-09-30 was $1.00M, a 66.67% increase year-over-year.
- LIFEVANTAGE CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-03-31 was $800.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month |
|---|---|---|---|---|
| 2024-03-31 | $800.00K 10-Q · filed 2024-05-02 | $1.60M derived: sum of 2 quarters · filed 2024-05-02 | $2.50M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $800.00K 10-Q · filed 2024-01-30 | $1.70M 10-Q · filed 2024-01-30 | ||
| 2023-09-30 | $1.00M 10-Q · filed 2023-11-09 | |||
| 2023-03-31 | $800.00K 10-Q · filed 2024-05-02 | $1.60M derived: sum of 2 quarters · filed 2024-05-02 | $2.20M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $800.00K 10-Q · filed 2024-01-30 | $1.40M 10-Q · filed 2024-01-30 | ||
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-09 | |||
| 2022-03-31 | -$38.00K 10-Q · filed 2023-05-04 | $762.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.40M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $800.00K 10-Q · filed 2023-02-02 | $1.40M 10-Q · filed 2023-02-02 | ||
| 2021-09-30 | $600.00K 10-Q · filed 2022-11-02 | |||
| 2021-03-31 | $700.00K 10-Q · filed 2022-05-03 | $1.70M derived: sum of 2 quarters · filed 2022-05-03 | $2.20M 10-Q · filed 2022-05-03 | |
| 2020-12-31 | $1.00M 10-Q · filed 2022-02-01 | $1.50M 10-Q · filed 2022-02-01 | ||
| 2020-09-30 | $500.00K 10-Q · filed 2021-11-04 | |||
| 2020-03-31 | $1.20M 10-Q · filed 2021-04-29 | $2.60M derived: sum of 2 quarters · filed 2021-04-29 | $4.00M 10-Q · filed 2021-04-29 | |
| 2019-12-31 | $1.40M 10-Q · filed 2021-02-02 | $2.70M 10-Q · filed 2021-02-02 | ||
| 2019-09-30 | $1.30M 10-Q · filed 2020-11-03 | |||
| 2019-03-31 | $1.00M 10-Q · filed 2020-05-05 | $2.00M derived: sum of 2 quarters · filed 2020-05-05 | $3.60M 10-Q · filed 2020-05-05 | |
| 2018-12-31 | $1.00M 10-Q · filed 2020-01-28 | $1.60M 10-Q · filed 2020-01-28 | ||
| 2018-09-30 | $600.00K 10-Q · filed 2019-10-30 | |||
| 2018-03-31 | $1.30M 10-Q · filed 2019-05-01 | $1.90M derived: sum of 2 quarters · filed 2019-05-01 | $2.30M 10-Q · filed 2019-05-01 | |
| 2017-12-31 | $600.00K 10-Q · filed 2019-02-04 | $1.00M 10-Q · filed 2019-02-04 | ||
| 2017-09-30 | $400.00K 10-Q · filed 2018-11-01 | |||
| 2017-03-31 | $600.00K 10-Q · filed 2018-05-09 | $900.00K derived: sum of 2 quarters · filed 2018-05-09 | $1.70M 10-Q · filed 2018-05-09 | |
| 2016-12-31 | $300.00K 10-Q · filed 2018-02-07 | $1.00M 10-Q · filed 2018-02-07 | ||
| 2016-09-30 | $700.00K 10-Q · filed 2017-11-08 | |||
| 2016-03-31 | $700.00K 10-Q · filed 2017-05-10 | $1.00M derived: sum of 2 quarters · filed 2017-05-10 | $1.20M 10-Q · filed 2017-05-10 | |
| 2015-12-31 | $300.00K 10-Q · filed 2017-02-08 | $500.00K 10-Q · filed 2017-02-08 | ||
| 2015-09-30 | $200.00K 10-Q · filed 2016-12-12 | |||
| 2015-03-31 | $600.00K 10-Q/A · filed 2016-07-19 | $1.10M derived: sum of 2 quarters · filed 2016-07-19 | $1.40M 10-Q/A · filed 2016-07-19 | |
| 2014-12-31 | $500.00K 10-Q · filed 2016-02-09 | $900.00K 10-Q · filed 2016-02-09 | ||
| 2014-09-30 | $400.00K 10-Q · filed 2015-11-04 | |||
| 2014-03-31 | $600.00K 10-Q · filed 2015-05-06 | $1.30M derived: sum of 2 quarters · filed 2015-05-06 | $2.00M 10-Q · filed 2015-05-06 | |
| 2013-12-31 | $700.00K 10-Q · filed 2015-02-04 | $1.50M 10-Q · filed 2015-02-04 | ||
| 2013-09-30 | $800.00K 10-Q · filed 2014-11-06 | |||
| 2013-03-31 | $600.00K 10-Q · filed 2014-05-06 | $585.00K 10-Q · filed 2013-05-09 | $1.20M derived: sum of 2 quarters · filed 2014-05-06 | $1.60M 10-Q · filed 2014-05-06 |
| 2012-12-31 | $600.00K 10-Q · filed 2014-02-06 | $562.00K 10-Q · filed 2013-02-07 | $1.10M 10-Q · filed 2014-02-06 | |
| 2012-09-30 | $500.00K 10-Q · filed 2013-11-07 | |||
| 2012-03-31 | $308.00K 10-Q · filed 2013-05-09 | $526.00K derived: sum of 2 quarters · filed 2013-05-09 | $881.00K 10-Q · filed 2013-05-09 | |
| 2011-12-31 | $218.00K 10-Q · filed 2013-02-07 | $573.00K 10-Q · filed 2013-02-07 | ||
| 2011-09-30 | $355.00K 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |